Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: results from the EMPA ‐REG OUTCOME® trial
ConclusionsIn Asian patients from EMPA ‐REG OUTCOME®, empagliflozin improved kidney outcomes, slowed eGFR decline and lowered albuminuria versus placebo, consistent with the overall trial population findings.This article is protected by copyright. All rights reserved.
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Takashi Kadowaki,
Masaomi Nangaku,
Stefan Hantel,
Tomoo Okamura,
Maximilian von Eynatten,
Christoph Wanner,
Audrey Koitka ‐Weber Tags: Original Article Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Jardiance | Urology & Nephrology